Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7002583 | 0.88 | L3MBTL1 (0.40) | L3MBTL1CTDSP1TDP1MAPTATM | |
| SCHEMBL6997105 | 0.86 | L3MBTL1 (0.44) | L3MBTL1CTDSP1TDP1MAPTATM | |
| SCHEMBL7110750 | 0.81 | HCRTR1 (0.37) | L3MBTL1 | |
| SCHEMBL6992115 | 0.78 | TDP1 (0.36) | L3MBTL1CTDSP1TDP1MAPTATM | |
| SCHEMBL6997493 | 0.77 | HTR7 (0.48) | — | |
| SCHEMBL6994168 | 0.75 | L3MBTL1 (0.40) | L3MBTL1CTDSP1TDP1ATMPTGDR2 | |
| SCHEMBL7105922 | 0.71 | HTR1A (0.37) | L3MBTL1 | |
| SCHEMBL7107466 | 0.71 | L3MBTL1 (0.44) | L3MBTL1CA9 | |
| SCHEMBL7109579 | 0.68 | HTR7 (0.37) | L3MBTL1 | |
| SCHEMBL7000061 | 0.67 | HTR1A (0.37) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664251-B2 | Serotonin receptor antagonist; treating cardiovascular disorder | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| EP-0686632-B1 | BENZOTHIAZINE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030078256-A1 | Benzothiazine derivative | SUNTORY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6316442-B1 | TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES | SUNTORY LIMITED (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6001827-A | Benzothiazine derivative | SUNTORY LIMITED (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5874429-A | ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS | SUNTORY LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0686632-A1 | BENZOTHIAZINE DERIVATIVE | SUNTORY LIMITED (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078256-A1 | Benzothiazine derivative | TPH2, ADRB2, TPH1 | L3MBTL1 227/4885CTDSP1 2741/4885PKM 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.